NK cells mediate innate as well as adaptive immune responses, including anti-tumoral cytotoxic activity; nevertheless, autologous NK therapy for patients with cancer has shown several limitations [47], such as difficulties in NK cell expansion ex vivo and the severe side effects observed after IL-2 treatment for NK cell activation [40]. This evidence concerns the gene IL2 and cancer.